Sun Pharma Announces US Launch of Authorized Generics for Olmesartan

Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office : SPARC, Tandalja, Vadodara – 390 020. India Corporate Office : SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India. FOR IMMEDIATE RELEASE Sun Pharma Announces US Launch of Authorized Generics for Benicar®, Benicar HCT ®, Azor® and Tribenzor® Mumbai, India, October 27, 2016 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN .BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” inclu ding its subsidiaries or associate companies) today announced that its wholly owned subsidiary has laun ched in US, the Authorized Generic (AG) versions fo r all strengths of: 1. Olmesartan Medoxomil tablets – therapeutic equivale nt of Daiichi Sankyo Inc.’s Benicar ® (olmesartan medoxomil) tablets; 2. Olmesartan Medoxomil-Hydrochlorothiazide tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Ben icar HCT ® (olmesartan medoxomil-hydrochlorothiazide) tablets; 3. Amlodipine Besylate-Olmesartan Medoxomil tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Azo r ® (amlodipine and olmesartan medoxomil) tablets; and 4. Amlodipine Besylate-Hydrochlorothiazide-Olmesartan Medoxomil tablets – therapeutic equivalent of Daiic hi Sankyo Inc.’s Tribenzor ® (olmesartan medoxomil, amlodipine, hydrochlorothiazide) tablets. The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly owned subsidiary and Daiichi Sankyo Inc., which grants the Sun Pharma su bsidiary, exclusive rights to distribute these tabl ets in the US for a pre-determined period. Benicar ®, Benicar HCT ®, Azor ® and Tribenzor ® recorded US sales of approximately US$ 2.5 billion for the 12 months ending August 31, 2016, as per IMS Health. ® - All brand names and trademarks are the property of respective owners. Disclaimer: Statements in this “Document” describing the Compan y’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, pe rformance or achievements could differ materially f rom those expressed or implied. Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office : SPARC, Tandalja, Vadodara – 390 020. India Corporate Office : SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India. About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050): Sun Pharma is the world's fifth largest specialty g eneric pharmaceutical company and India's top pharm aceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quali ty, affordable medicines trusted by customers and p atients in over 150 countries across the world. Sun Pharma's global pre sence is supported by 47 manufacturing facilities s pread across 6 continents, R&D centres across the globe and a mult i-cultural workforce comprising over 50 nationaliti es. The consolidated revenues for 12 months ending March 2016 are approximately US$ 4.3 billion, of which US contributes US$ 2.1 billion. In India, the Company enjoys leadership across 12 different classes of doctors with 32 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging mark ets covers over 100 markets and 6 markets in Wester n Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footpr int is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence th rough innovation supported by strong R&D capabilities comprising abo ut 2,000 scientists and R&D investments of over 8% of annual revenues. For further information please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live Contacts: Sun Pharma Nimish Desai Frederick Castro Tel +91 22 4324 4324, Xtn 2778 Tel +91 22 4324 432 4, Xtn 2777 Tel Direct +91 22 4324 2778 Tel Direct +91 22 4324 2777 Mobile +91-98203 30182 Mobile +91 99206 65176 E mail [email protected] E mail frederick [email protected]

The release as fetched from its publisher. sunpharma.com ↗